GSK3B and breast carcinoma: The profound increase in P-GSK3 β was more detected in resistant variants of both cell lines (Fig 5B), which is in line with a previous study that showed blocking GSK-3β activity may lead to drug and hormonal resistance and modify sensitivity to targeted therapy in MCF-7 breast cancer cells [41].